Research Coverage


Code: 4563Last Update:
Research Reports
Download Research Report

Since the company’s establishment in 1999, HGF gene therapy drug (a new drug candidate; regenerates blood vessels by medicating HGF –hepatocyte growth factor--genes) has been the mainstay pipeline drug for AnGes. The company has continued to post operating losses, with the exception of FY12/01 prior to its public listing. By August 2017, the company had not brought to market any self-developed drugs. Sales are limited to development cooperation payments and milestone payments from partner pharmaceutical companies, plus Naglazyme sales.

Our Policy

We interview management for hours, asking exhaustive questions to uncover the essence of the business.

We pinpoint strengths and weaknesses, and discuss strategy. Our aim is to make deep knowledge about the company readily available, saving investors time and enabling dialogue.

Our Research

We start our coverage with a substantial core report. We then continuously update this report to reflect earnings, newsflow, and any material developments. We interview the management quarterly to help you stay on top of the story.

Our report is an authoritative Owner’s Manual of the company—a vital piece in the investor’s toolbox.

For Investors

If you find our efforts valuable, please tell companies you want them to join our growing client list.